It was a delight to be able to speak with Dr Carlos Chaccour (University of Barcelona, Barcelona, Spain) about the controversy currently surrounding the use of ivermectin for the treatment of COVID-19.
His presentation entitled Ivermectin and COVID: what’s going on? was presented at the ISNTD d3 2021 Virtual Congress, 24-25 February.
- Could you give us a brief overview of the controversy surrounding the use of ivermectin for the treatment of COVID-19? (0:49)
- What evidence has been generated to date to help support the case for and against the drug’s use? (3:53)
- What further evidence is emerging on the efficacy of ivermectin in this indication? (6:36)
Disclosures: Dr Carlos Chaccour has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media
Filmed in coverage of ISNTD d3 2021 Virtual Conference.
Share this Video
Related Videos In COVID-19
Rifaat Safadi, EASL ILC 2021: Impact of Liver Disease on SARS-CoV-2 Vaccine Response
It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines. His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL […]
Timothy Hinks, ECCMID 2021: ATOMIC2 Study Results
touchINFECTIOUSDISEASES were pleased to meet with Timothy Hinks (Nuffield Department of Medicine, University of Oxford, Oxford, UK) to discuss the results of the ATOMIC2 study results, investigating azithromycin in the treatment of COVID-19. The abstract entitled: ‘A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19: the ATOMIC2 trial’ was presented at the […]
Beatriz Mateos, EASL ILC 2021: Tenofovir in Hepatitis B Patients with COVID-19
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B. Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!